Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16804993 | 0.89 | FAAH (0.42) | FAAHLMNAMMP2MMP13MMP14 | |
| SCHEMBL16783072 | 0.84 | LMNA (0.43) | FAAHLMNAMMP2MMP13MMP14 | |
| SCHEMBL16804977 | 0.76 | LMNA (0.51) | FAAHLMNAMMP2MMP13MMP14 | |
| SCHEMBL16804979 | 0.74 | LMNA (0.46) | FAAHLMNAMMP2MMP13MMP14 | |
| SCHEMBL21605634 | 0.72 | FAAH (0.43) | FAAHLMNAKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL16804975 | 0.72 | MMP2 (0.42) | FAAHLMNAMMP2MMP13MMP14 | |
| SCHEMBL21605651 | 0.71 | FAAH (0.41) | FAAHKMT2A | |
| SCHEMBL16804989 | 0.71 | MMP2 (0.41) | FAAHLMNAMMP2MMP13MMP14 | |
| SCHEMBL16808954 | 0.70 | LMNA (0.43) | FAAHLMNAMMP2MMP13MMP14 | |
| SCHEMBL16804990 | 0.70 | RXRA (0.35) | MMP2MMP13MMP14KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015090579-A1 | PYRAZOLYL-BASED CARBOXAMIDES IV | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015090579-A1 | PYRAZOLYL-BASED CARBOXAMIDES IV | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | AADAC, NLRP3, NOD2 | FAAH 1619/4885LMNA 738/4885MMP2 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.